SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 2003; 97: 6370.
  • 2
    Warde P, Sturgeon J, Gospodarowicz M. Testicular cancer. In: Clinical radiation oncology. GundersonL, TepperJ, eds. Philadelphia: Churchill Livingstone; 2000: 844862.
  • 3
    Ingelfinger JA, et al. Biostatistics in clinical medicine. 3rd ed. New York: McGraw-Hill; 1994.
  • 4
    HigginsJPT, GreenS, eds. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]. In: Cochrane library, Issue 3, 2005. Chichester, UK: John Wiley; 2005.
  • 5
    Collett D. Modelling survival data in medical research. 1st ed. London: Chapman and Hall; 1994.
  • 6
    Cleveland W. Robust locally weighted regression and smoothing scatterplots. JASA. 1979; 74: 829836.
  • 7
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977; 35: 139.
  • 8
    Team RDC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2005.
  • 9
    Oliver RT, Edmonds PM, Ong JY, et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys. 1994; 29: 38.
  • 10
    Oliver RTDT, Boubilkova L, Ong J. Fifteen-year follow-up of the Anglian Germ Cell Cancer group adjuvant studies of carboplatin as an alternative to radiation or surveillance for stage 1 seminoma [abstract]. Proc Am Soc Clin Oncol 20: 2001. Abstract 780.
  • 11
    Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005; 366: 293300. Comment in: Lancet. 2005; 366: 267–268.
  • 12
    Warde P, Specht L, Horwich A, et al., Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002; 20: 44484452. Comment in: J Urol. 2003; 170: 1041.
  • 13
    Horwich A, et al. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer. 1992; 65: 775778.
  • 14
    Warde PR. Chung P, Sturgeon J, et al. Should surveillance be considered the standard of care in stage I seminoma? [abstract]. J Clin Oncol. 2005; 23(16 suppl ). Abstract 4520.
  • 15
    Aparicio J, Germa JR, Garcia Del Muro X, Maroto P, Sachez A. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol. 2005; 23: 87178723.
  • 16
    Choo R, Thomas G, Woo T, Lee D, Chandler S. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Rad Oncol, Biol, Phys. 2005; 61: 736740.
  • 17
    Aparicio J, Garcia del Muro X, Maroto P, et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol. 2003; 14: 867872.
  • 18
    Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. Apmis. 2003; 111: 7683.
  • 19
    von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer. 1993; 29A: 19311934.
  • 20
    Niazi TM, Souhami L, Sultanem K, Bahoric B, Gilbert L, Stanmir G. Long-term results of para-aortic irradiation for patients with stage I seminoma of the testis. Int J Rad Oncol, Biol, Phys. 2005; 61: 741744.
  • 21
    Classen J, Schmidberger H, Meisner C, et al. Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer. 2004; 90: 23052311.
  • 22
    Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005; 23: 12001208.
  • 23
    Schultz HP, von der Maase H, Rorth M, Pedersen M, Sandberg Nielsen E, Walbom-Jorgensen S. Testicular seminoma in Denmark 1976–1980. Results of treatment. Acta Radiol Oncol. 1984; 23: 263270.
  • 24
    Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999; 17: 1146.
  • 25
    Krege S, Kalund G, Otto T, Goepel M, Rubben H. Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol. 1997; 31: 405407.
  • 26
    Argirovic D. Germ cell testicular tumors in clinical stage A and normal values of serum tumor markers post-orchiectomy: the experience in the management of 300 consecutive patients. J B.U.ON. 2005; 10: 195200.
  • 27
    Dieckmann KP, Bruggeboes B, Pichlmeier U, Kuster J, Mullerleile U, Bartels H. Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology. 2000; 55: 102106.
  • 28
    Oldenburg J, Alfsen GC, Waehre H, Fossa SD. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer. 2006; 94: 820827.
  • 29
    Oliver T. One-dose carboplatin in seminoma. [comment]. Lancet. 2005; 366: 1526.
  • 30
    Logue JP, Harris MA, Livsey JE, Swindell R, Mobarek N, Read G. Short course para-aortic radiation for stage I seminoma of the testis. Int J Radiat Oncol Biol Phys. 2003; 57: 13041309.
  • 31
    Fitzgerald R, Twiss D, Mehra R, Evans M, Qaiyum M, Collins M. Low-dose computed tomography surveillance of patients with testicular tumours. Clin Oncol (R Coll Radiol). 2004; 16: 158.
  • 32
    Nathan PD, Rustin GR. The role of CT scanning in the surveillance of testicular tumours. Clin Oncol (R Coll Radiol). 2003; 15: 121122. Comment in: Clin Oncol (R Coll Radiol). 2003; 15: 441–442.
  • 33
    Berrington de Gonzalez A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet. 2004; 363: 345351. Comments in: Lancet. 2004; 363: 340–341. Lancet. 2004; 31: 1908–1909; author reply 1910.
  • 34
    Dalal PU, Sohaib SA, Huddart R. Imaging of testicular germ cell tumours. Cancer Imaging. 2006; 6: 124134.
  • 35
    Raghavan D. Hidden by HIPAA: the costs of cure. J Clin Oncol. 2005; 23: 36633665. Comment in: J Clin Oncol. 2005; 23: 3718–3725.